Related Experiment Video
Updated: Jun 24, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Prognostic/Predictive molecular markers in colorectal cancer
1Professor of Medicine and Preventive Medicine, Co-Director, Colorectal Center, GI Oncology Program, USC/Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, CA.
Gastrointestinal Cancer Research : GCR
|April 11, 2009
Summary
Identifying molecular markers can improve prognostic assessment for stage II colon cancer patients, guiding adjuvant therapy decisions. Further validation in larger populations is crucial for clinical application.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Clinicopathologic staging for stage II colon cancer lacks sufficient prognostic detail for adjuvant therapy decisions.
- There is a need for molecular prognostic and predictive markers to better assess patient risk and therapy response.
Purpose of the Study:
- To evaluate molecular markers, including chromosome 18q21 loss of heterozygosity (LOH) and microsatellite instability, for prognostic assessment in stage II colon cancer.
- To explore the potential of germline polymorphisms and molecular signatures in predicting recurrence risk and guiding treatment strategies.
Main Methods:
- Analysis of chromosome 18q21 LOH and microsatellite instability in an adjuvant therapy trial for stage II colon cancer.
- Investigation of germline polymorphisms in angiogenesis-related genes.
- Application of microarray techniques to identify molecular signatures for risk stratification.
- Candidate gene identification approaches to find genes associated with recurrence risk.
Main Results:
- Molecular signatures identified via microarray analysis show promise in discriminating risk within clinicopathologic stages.
- Candidate gene approaches have identified numerous genes linked to recurrence risk.
- Germline polymorphisms, particularly in angiogenesis genes, are associated with varying recurrence risks.
Conclusions:
- Molecular markers and signatures hold significant potential for improving prognostic accuracy in stage II colon cancer.
- Validation in larger patient cohorts, standardization of analyses, and prospective clinical trials are essential next steps for clinical implementation.
